Key facts
- This page summarizes Wellington Biomedical Innovation Master Investors (Cayman) II L.P.'s Form 4 filing for RayzeBio, Inc..
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 19 Sep 2023, 19:41.
Wellington Biomedical Innovation Master Investors (Cayman) II L.P. - 19 Sep 2023 Form 4 Insider Report for RayzeBio, Inc.
- Reporting relationship
- 10%+ Owner
- Issuer ticker
- N/A
- Reported as of
- 19 Sep 2023
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 19 Sep 2023, 19:41:36 UTC
- Prior SEC filing
- 14 Sep 2023
- Next SEC filing
- 16 Nov 2023
- Source filing
- View source filing
- Reporting owner signature
- Wellington Biomedical Innovation Master Investors (Cayman) II L.P., By: Wellington Management Company LLP, as Investment Adviser, /s/ Peter McIsaac, Title: Authorized Person
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Wellington Biomedical Innovation Master Investors (Cayman) II L.P. filed Form 4 for RayzeBio, Inc. on 19 Sep 2023.
Change
- Previous filing in this sequence was filed on 14 Sep 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
RYZB
transaction
Common Stock
Conversion of derivative security
- Transaction value
- Shares
- +1,557,846
- Change %
- Price
- Shares after
- 1,557,846
- Date
- 19 Sep 2023
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
RYZB
transaction
Derivative
Series D Preferred Stock
Conversion of derivative security
- Transaction value
- $0
- Shares
- -1,557,846
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 19 Sep 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 1,557,846
- Exercise price
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Section 16 status
Wellington Biomedical Innovation Master Investors (Cayman) II L.P. is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Explanation of responses 1 footnote
Footnote F1
Upon the closing of the Issuer's initial public offering, each share of Series D Preferred Stock automatically converted into one share of the Issuer's Common Stock. The Series D Preferred Stock had no expiration date.